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4. Introduction 
Heart failure (HF) is the common endpoint of heart disease of various etiologies, and is a 
major cause of hospitalizations and death worldwide(1-3). Essentially, HF represents a 
pathophysiologic state of impaired cardiac function in which the heart is unable to maintain 
cardiac output sufficient for adequate perfusion of organs and tissues (4; 5). Coronary artery 
disease, hypertension, cardiomyopathies and valvular disease represent major causes of HF. 
Projections are that the prevalence likely will increase as a consequence of increasing mean 
age of the population (6; 7). Furthermore, increased survival from myocardial infarction (MI) 
will leave more patients living with HF(8). Even with the best treatment currently available, 
the overall 5-years mortality of HF is still over 50% and thus, hardly better than that of many 
types of cancer, reflecting the fact that the pathogenetic mechanisms underlying HF are still 
incompletely understood. In addition to reduced capacity of the heart to pump blood, HF is 
associated with activation of pro-inflammatory responses and mediators which itself can lead 
to progressive deterioration of cardiac function(9-11). More detailed knowledge of molecular 
mechanisms of HF has become a subject of intensive research. Chronic alterations in structure 
and geometry of the cardiac muscle, so-called remodeling, are widely found in heart failure 
patients(12; 13). Left ventricular (LV) remodeling itself is a progressive  process which often 
is initiated by stress events or biomechanical loading such as myocardial infarction and poorly 
controlled hypertension(12; 13). As a paradigm, remodeling can either be predominantly 
eccentric (i.e. the heart is dilating), concentric (muscle mass is increasing) or a combination of 
both(13; 14).  Basic research and translation of its results into clinical trials has seen major 
recent advances and led to the establishment of new treatment modalities targeting –
adrenergic signaling, Ang II and aldosterone activation(15-18).  
Cardiac function is controlled by the autonomic nervous system, hormones, and diverse 
autocrine, endocrine or paracrine factors. G protein-coupled receptors (GPCR) comprise a 
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major class of receptors, and are in fact one of the largest known protein families(19). GPCRs 
are involved in most fundamental biological signaling processes, and in essence in most of 
mammalian tisssues(20; 21). The vital importance of GPCR signaling in cardiac disease is 
illustrated by the fact that the vast majority of current cardiovascular drugs target specific 
GPCRs, such as 1-AR, angiotensin type-II receptors, aldosterone or endothelin (ET) 
receptors(17; 18; 22; 23). 
Increasing knowledge of signaling mechanisms in cardiac physiological and pathological 
states will be crucial for improving treatment of the HF and its precursing disease entities. 
Furthermore, targeted interaction with key pathophysiological signaling mechanisms holds 
the potential of preventing evolution to cardiac hypertrophy and HF upon given stress signals, 
as has been shown in numerous experimental studies. The present work aims to explore novel 
molecular mechanisms in hypertrophy and HF, as well as to investigate potential therapeutic 
principles. 
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Fig. 1   Adaptive and maladaptive cardiac hypertrophy (modified from Frey et. al. (24)) 
 
Cardiac hypertrophy and remodeling in heart failure 
Cardiac hypertrophy, i.e. excessive growth of the heart, can initially occur by cardiomyocyte 
hyperplasia, but primarily by increase of cell mass. Postnatal cardiac growth is a normal 
physiological phenomenon aiming at increasing heart size, i.e. to maintain cardiac output in 
the growing organism or to meet increased bodily demands during exercise training.  
Pathological stimuli such as catecholamine excess or increased afterload can lead to 
maladaptive cardiac hypertrophy, as seen in hypertension or aortic stenosis. Multiple 
signaling and transcription pathways are involved in this process, leading to hypertrophic 
remodeling of the LV (fig. 1)(24; 25). This type of LV hypertrophy (LVH) is an independent 
risk factor for cardiac morbidity and mortality(26). In HF patients, elevated levels of 
catecholamines are frequently seen(27; 28). Sustained adverse stimulation will increase 
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cardiomyoctes and thus, cardiac mass, both through increased afterload or direct cardiac 
effects. Among the adrenergic receptors, 1-AR couple to the hetrotrimeric G-protein Gq. 
Upon agonist activation, the Gq unit activates phospholipase C, which increases inositol-
1,4,5-triphosphate and diacylglycerol. The former increases intracellular calcium, while the 
latter leads to further activation of PKC isozymes(29). The Gq pathway has been extensively 
studied for its importance in cardiac hypertrophy and HF(30). Based on a body of largely 
experimental evidence; one may suggest that factors leading to hyperactive Gq signaling 
predispose to cardiac hypertrophy, and potentially, transition to decompensated HF(31-35). 
Neuroendocrine factors and cytokines such as ET-1 and AT-II promote activation of 
important downstream signaling cascades including MAPK, calcineurin, NFAT/GATA4, 
PKC, CaMK, and IGF-1 pathway constituents(36; 37). One important issue relating to GPCR-
mediated hypertrophy and HF is to delineate specific signaling complexes in order to 
ascertain critical intracellular events regulating the hypertrophic response and transition to 
HF(38). 
 
Endothelin system  
Endothelin (ET) is a 21-amino acid peptide first isolated from porcine endothelial cells.(39) 
Three isoforms encoded by separate genes exist; ET-1, ET-2 and ET-3(39; 40). ET-1, the 
major isoform of the endothelin peptide family in the cardiovascular system, is among the 
most potent vasoconstrictors (~100 x norepinephrine) known to date, and possesses as 
positive inotropic and chronotropic effects (41-44), mitogenic effects on smooth muscle cells 
(45), influence on salt and water homeostasis, and stimulation of the renin-angiotensin-
aldosterone (RAAS) and sympathetic nervous systems (for reviews, see (46; 47) (fig. 2).  
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Fig. 2   The vascular endothelin (ET) system (modified from Kirkby et al (48)) 
 
ET-1 is essential for normal embryonic development (49; 50). The biosynthesis of ET-1 
occurs through several proteolytic steps to form the prohormone prepro-ET, the inactive 
intermediate big ET-1, which is subsequently processed by endothelin-converting enzyme 
(ECE) into biologically active ET-1 (Fig. 2)(51). Two isoforms of ECE with distinct pH-
optima, ECE-1 and ECE-2, with 4 and 2 subtypes, respectively, have been characterized(51-
55). In vivo, the activity of ECE-1 appears to be the rate-limiting step in ET-1 
biosynthesis(56; 57).  
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Table 1. Function of ET receptors in the cardiovascular system. 
Cell type ETA receptors ETB receptors 
Cardiomyocytes Hypertrophy(58) 
Positive inotropy(41) 
Protection from apoptosis(59) 
Positive chronotropy(42) 
Hypertrophy? 
Cardiac fibroblasts Growth, fibrosis(60-62) Growth, fibrosis(63; 63; 64) 
Endothelial cells  Vasodilation through the 
release of NO and 
prostacyclin(65) and 
adrenomedullin(66) 
ET-1 clearance/reuptake(67) 
Increased ET-1 gene 
expression(68) 
Vascular smooth muscle 
cells 
Vasoconstriction, growth (45; 
69) 
Vasoconstriction(70) 
 
ET-1 is mainly produced by endothelial, vascular smooth muscle cells, and macrophages and 
acts through binding to Gq-protein-coupled ETA and ETB receptors(71). In the cardiovascular 
system, ETAR and ETB R signaling produces distinct effects (table 1). Within the vasculature, 
ET-1 is secreted predominantly abluminally, i.e. on the basal side of endothelial cells to act on 
vascular smooth muscle cells (VSMC)(72), resulting in substantially higher concentrations 
within the vascular wall compared to plasma levels. Under normal physiological conditions, 
ET-1 plasma levels are low, with ET-1 acting rather as a paracrine factor(73). In cardiac 
disease such as HF, ET-1 levels are elevated and thought to derive primarily from spillover in 
the vasculature(74-79). Several reports have shown that the pulmonary circulation contributes 
to circulating plasma ET-1 levels in HF(80; 81). The synthesis and secretion of ET-1 by 
endothelial cells is increased by various growth factors, cytokines and vasoactive factors, such 
as Ang II, vasopressin, bradykinin, norepinephrine and ET-1 itself (82). Low shear stress 
increases ET-1 mRNA, while high shear stress decreases it (83; 84). The clearance of ETs 
from plasma may occur through cleavage by neutral endopeptidase EC3.4.24.11 (85), and 
through binding to ETBR, which especially in the lung acts as a clearance receptor (86; 87). 
Due to effective clearance, the plasma half life of infused ET-1 is only one minute (47). 
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Importantly, ET-1 contributes in the pathogenesis of post-MI remodeling and HF, and plasma 
levels strongly predict mortality and morbidity(75; 76; 88-90). In this condition, ET-1 
increases afterload by peripheral ETAR mediated vasoconstriction(91-93). Moreover, ET-1 
levels are increased in relation with the severity of pulmonary arterial hypertension (PAH) in 
HF; likewise, ETR inhibition ameliorate the degree of PAH in animals and patients with 
HF.(94-98). On the contrary, short-term therapy aimed at lowering afterload and elevated 
filling pressures in HF patients rapidly reduced ET-1 and neurohormonal activation (99). 
Based on encouraging experimental data (100) and human hemodynamic studies, several 
randomised controlled trials (RCT) have explored the putative benefit of ETR blockade in HF 
patients (table 2). Both dual or non-selective receptor blockers (targeting ETAR and ETBR) 
and selective ETAR blockers have been employed. To date, the vast majority of these trials 
have failed to show improved outcome. However, in patients with isolated PAH, an 
infrequent yet rapid progressive and incurable cardiovascular disease leading to right-sided 
HF, non-selective ET receptor blockade has consistently demonstrated favourable 
outcomes(101). For this type of patients, ET-1 receptor blockers Bosentan, and more recently, 
Sixtasentan and Ambrisentan, have been added to the list of efficient pharmacotherapy(102). 
Despite recent major advances in ET research, many aspects of ET biology and in particular, 
origin, role and fate of elevated plasma ET-1 in HF are still poorly understood. 
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Inflammation in heart failure 
Among multiple compensatory processes being activated as beforementioned, chronic HF is 
characterized by inflammatory reponses and activation of the innate immunity.  Recently it 
has been shown that patients with HF have increased plasma and myocardial levels of 
inflammatory cytokines(9; 10; 119-123). Among proposed mechanisms for this immune 
activation, which are not mutually exclusive, are neurohormonal activation, hemodynamic 
overload, and activation of the innate immune system secondary to cardiac stress events, i.e. 
myocardial infarction. Experimental data have demonstrated a role for inflammatory and 
vasoactive cytokines such as tumor necrosis factor- (TNF-), interleukin-1 (IL-1), ET-1, and 
monocyte chemoattractant peptide-1 (MCP-1), all of which may contribute to the 
development and progression of HF by promoting myocardial hypertrophy or dysfunction, 
extracellular matrix remodeling, inducing apoptosis(9; 10; 119-124). Uncertainties exist as to 
the organ and cellular source of many of these cytokines, but the clinical significance is 
illustrated by a consistent and significant correlation of plasma levels and clinical 
outcomes(122; 125-128). Both TNF- and ET-1 are such proinflammatory cytokines which 
can be produced by macrophages. Importantly, cardiac overexpresion of TNF-  (129) or ET-
1 (130) in mice leads to similar phenotype of inflammatory cardiomyopathy. Currently, only 
few experimental and human studies have addressed the question whether targeting of an 
overactivated immunity in HF may carry benefit. “Single target” approaches such as blockade 
of TNF- receptor in patients with HF have not demonstrated outcomes superior to 
conventional treatment, while more broad-based anti-inflammatory strategies demonstrated 
clinical improvements (131-135). More research in this area is needed to precisely identify 
important mechanisms in the immunopathogenesis of chronic HF which then could be 
counteracted pharmacologically. 
 
 16
G protein-coupled receptor signaling and desensitization in HF 
Cardiac output is normally regulated by the autonomic nervous system and can be increased 
through release of stress hormones such as catecholamines. Catecholamines such as 
norepinephrine transmit their “message” through G protein-coupled receptors (GPCR), whose 
common feature is a seven-transmembrane span and their ability to activate heterotrimeric  
G-proteins. Activation of G-proteins initiates transduction of the extracellular signal to 
intracellular effector molecules(136). In the heart, GPCRs signaling may regulate function by 
modulating heart rate and contractility, or structure by inducing events such as cell growth or 
death (apoptosis). As a typical example for the GPCR-related signaling cascades, agonist 
binding to 1-adrenergic receptors (1-AR) in the heart will activate the G protein Gss (s, 
stimulatory). Activated Gss will then activate adenylate cyclase (AC), leading to AC-
catalyzed synthesis of cAMP. Functioning as a second messenger, cAMP then activates 
protein kinase A (PKA), leading to positive chronotropy (increased heart rate), inotropy 
(increased contractile force) and lusitropy (quicker relaxation)(137-140). 1-adrenergic 
receptors (1-AR) are the predominant cardiac GPCRs activated by endogenous 
norepinephrine and epinephrine, with minor contributions by 2-AR and, at least in some 
mammalian species, 1-AR(141; 142). In HF irrespective of the initiating event, 
compensatory mechanisms such as augmentation of 1-AR signaling are rapidly activated, in 
order to maintain sufficient cardiac output. This is afforded at the cost of increased heart rate 
and myocardial oxygen consumption. Prolonged activation of 1-AR, moreover, can induce 
programmed cell death of heart muscle cells (cardiomyocyte apoptosis), reduced number as 
well as reduced response of receptors, and ultimately worsening of cardiac function(142; 
143). The deleterious consequences of chronic neurohormonal overactivation suggest an 
important protective role for mechanisms which desensitize neurohormone-mediated GPCR 
responses in HF.  Based on these fundamental molecular events, 1-AR blockade has 
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emerged as a major therapeutic principle in heart failure during the last decade. Activation of 
the renin-angiotensin-aldosterone system (RAAS) is another important mechanism activated 
in HF, leading to increased circulating and myocardial levels of the vasoconstrictor peptides 
renin and angiotensin II as well as the mineralocorticoid hormone aldosterone. All of these 
three components of the RAAS are established or emerging drug targets in heart failure(15-
18). In HF, loss of response due to prolonged or augmented activation of GPCRs such as the 
-AR has been identified, a phenomenon termed receptor desensitization (138; 144-146). 
Receptor desensitization can occur quickly, experimentally even after a few seconds or 
minutes. Also, desensitization can either be limited to agonists acting at a particular GPCR 
subtype, referred to as homologous desensitization, or represent a more general loss of agonist 
responsiveness involving several GPCR even in the absence of agonist occupation of these 
receptors. The former usually involves changes at the level of the GPCR itself, while the latter 
may involve adaptive changes in downstream signaling components. Importantly, 
desensitization is a process distinct from GPCR downregulation, which involves lysosomal 
degradation of GPCRs. Even excessive GPCR desensitization does not necessarily lead to 
downregulation, but both can occur simultaneously, adding to loss of functional response 
upon agonist stimulation. An important mechanism in the ´classical´ model of agonist-
induced desensitization is phosphorylation of the GPCR(147). Phosphorylation is catalyzed 
by a family of kinases termed G protein coupled receptor kinases (GRK). GRK have been 
demonstrated to play a key role in agonist-induced phosphorylation and desensitization of 
numerous GPCR mediated responses. The classical model for agonist-occupied 
desensitization of GPCR involves phosphorylation of serine or threonine residues on the 3rd 
intracellular loop or COOH- terminus of the GPCR(148).  Arrestins, members of another 
family of regulatory proteins, then bind to the GRK-phosphorylated GPCR with high affinity, 
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uncoupling it from further G-protein activation, thus inducing desensitization of the GPCR.  
 
Fig. 3   The G protein-coupled receptor kinase (GRK) family 
 
G protein-coupled receptor kinases (GRKs) 
GRKs constitute a family of seven serine/threonine protein kinases which are further 
subdivided into three main subgroups, i.e. visual GRKs or the rhodopsin kinase subfamily 
(GRK1 and GRK7), the ARK kinase subfamily including GRK2 (ARK1) and GRK3 
(ARK2), and the GRK4 family (GRK4, GRK5, and GRK6) (fig. 3)(149). 
In myocardial tissue, 4 different GRKs have been found, GRK2, 3, 5 and 6. Of these, GRK2 
and GRK3 share important structural similarities. In contrast to the other GRKs, GRK2 and 
GRK3 possess a carboxy-terminal (CT) pleckstrin-homology (PH) domain important for 
membrane targeting and binding to G-protein subunits(149). GRK2, initially termed ARK1, 
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has been shown to mediate desensitization of myocardial -AR(150; 151). In experimental 
and human HF upregulation of myocardial GRK2 is found(152; 153). Inhibition of GRK2 in 
genetically engineered mouse models of heart failure, such as the muscle lim protein–
knockout model and cardiac-specific overexpression of calsequestrin, and in a number of 
experimental settings has provided robust evidence of improving cardiac function and 
survival(150; 154-159). Although similar overall structure, GRK3 has distinct substrate 
spesificities determined by the CT domain. While GRK2 regulates cardiac -AR and Ang II-
R, 1-ARs are not touched by it(150; 160; 161). Vice versa, GRK3 strongly modulates 
cardiac 1-AR, ET-R and thrombin receptor mediated responses without altering 1-AR 
mediated responses or receptor internalization(160-162). Accordingly, GRK2 and GRK3 
seem to have distinct substrate specificities at least within the cardiovascular system (table 3). 
The role of myocardial GRK3 is little studied, as is its potential involvement in cardiac 
disease states, and the role of GRK5 and GRK6 are almost unknown. Several powerful 
molecular strategies have emerged during the last decade and proven valuable tools to study 
GRK isozyme function in vitro and in vivo.  
Table 3. Substrate preferences of GRK2 and GRK3 in cardiovascular tissues. 
Receptor GRK2 GRK3 References 
1 + - (150; 160; 162) 
2 + - (163) 
1 - + (160-162) 
ET - + (162) 
Angiotensin II + - (160; 164) 
Thrombin - + (160; 165; 166) 
Muscarinic ? +(?)  (167) 
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5. Aims of the Study 
This work aimed to elucidate molecular mechanisms involved in the pathophysiology of 
cardiac hypertrophy and heart failure. 
The specific aims of the study were: 
1)  to identify the origins of increased plasma ET-1 levels in HF 
2) to elucidate the mechanism of increased pulmonary secretion of ET-1 in 
experimental HF 
3) to investigate whether depletion of macrophages reduces pulmonary ET-1 
secretion and progressive cardiac remodeling in HF 
4) to elucidate the role of GRK3 in regulation of myocardial function in vivo 
5) to investigate to what extent inhibition of GRK3 in vivo alters development of 
pathological cardiac hypertrophy and HF after pressure-overload 
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6. Summary of Results 
Paper  
Juvenile pigs subjected to three weeks of rapid cardiac pacing exhibited significant left 
ventricular dilatation and dysfunction, increased cardiac filling pressures, and over 4-fold 
increase of arterial plasma ET-1 levels, consistent with induction of severe HF. Repeated 
investigations showed an increasing trans-pulmonary gradient of plasma ET-1 during 
evolving HF. Single-bolus multiple indicator-dilution experiments revealed increased 
pulmonary synthesis and release of ET-1 in HF, with pulmonary clearance of ET-1 remained 
unaltered. ECE-1 isozyme activity was selectively increased in congested pulmonary tissue of 
HF pigs, and correlated significantly with the wet/dry weight ratios of the samples, i.e. a 
marker of pulmonary congestion. Furthermore, pulmonary macrophages (PM) in congested 
lobe segments were identified as likely sites of increased synthesis and release of ET-1. 
Paper II 
Two weeks (baseline) after induction of myocardial infarction by coronary ligation, rats in 
severe HF were randomized to treatment with the macrophage toxicant gadolinium chloride 
GdCl3 (HF-Gad) or vehicle (HF-V) for 21 days (end-point). In HF-Gad compared to HF-V 
rats, massive apoptosis of PM and lower pulmonary tissue levels of the macrophage-derived 
cytokines IL-12A and IL-12B and ET-1 were found. Arterial plasma ET-1 levels were 
increased 6-fold in HF-V rats vs. sham-operated rats.  Depletion of PM led to reduced arterial 
plasma ET-1 levels and eliminated the trans-pulmonary gradient of ET-1. Moreover, HF-Gad 
rats exhibited halted progression of cardiac dilatation and dysfunction and significantly 
reduced filling pressures.  
Paper  
Cardiac function of GRK3 was investigated in transgenic mice (Tg-GRK3ct) with cardiac-
specific expression of the carboxyl-terminal portion of GRK3 (GRK3ct) to inhibit its 
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activation through G-directed membrane translocation. Tail-cuff plethysmography of 3-9 
months old Tg-GRK3ct mice revealed modest hypertension compared to non-transgenic 
littermate control (NLC) mice, an observation confirmed by blood pressure radiotelemetry of 
conscious, unrestrained mice. Heart rate, however, was similar between Tg-GRK3ct and NLC 
mice. Young Tg-GRK3ct mice (3 months) had normal cardiac dimensions but enhanced 
contractility. Moreover, Tg-GRK3ct mice displayed supersensitivity to 1-adrenergic receptor 
stimulation, while response to chronic 1-adrenergic receptor stimulation was unaltered. 
Pressure-volume relationships obtained in electrically paced ex vivo-perfused working hearts 
confirmed hypercontractile myocardium with elevated dP/dtmax, LV developed pressure, 
cardiac output, and stroke work in Tg-GRK3ct mice at physiological filling pressures.  
Paper IV 
Here we sought to elucidate the putative role of myocardial GRK3 in the development of 
pathological cardiac hypertrophy and HF. Tg-GRK3ct and NLC mice were subjected to 
chronic pressure-overload by suprarenal abdominal aortic banding (AB). Six weeks after AB, 
pressure-volume analysis of ex vivo perfused working hearts revealed substantial systolic and 
diastolic cardiac dysfunction in NLC mice, while cardiac function was entirely preserved in 
banded Tg-GRK3ct mice. Cardiac and LV mass was significantly enhanced in banded 
compared to their respective sham groups confirming LVH, but without significant 
differences between banded Tg-GRK3ct and NLC mice. At 12 weeks after AB, NLC mice 
displayed increased LV filling pressures, reduced cardiac output and augmented myocardial 
mRNA levels of BNP consistent with HF, all of which were prevented in banded Tg-GRK3ct 
mice.  
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7. Discussion 
This thesis sheds light on novel molecular mechanisms involved in the pathogenesis of 
myocardial hypertrophy, LV remodeling, and HF. Comprehensive integrative physiology and 
molecular techniques were applied in a range of ischemic and non-ischemic HF models in 
pigs, rats and mice, to elucidate important components of GPCR signaling.  
 
Origin and mechanisms of elevated ET-1 levels in HF 
In a large animal model of tachycardia-induced HF, we studied the tissue-specific and cellular 
origin of increased plasma ET-1 levels. In HF, ET-1 may act in a endocrine fashion, and 
several reports have indicated the lungs to play a contributing role to increased plasma levels, 
but the relative importance of the pulmonary compared to other vascular beds had not been 
established(80; 81). We here not only demonstrate the pulmonary circulation to be the most 
important source of elevated plasma ET-1, but also show that the trans-pulmonary gradient of 
ET-1 increased with progression of HF. The lungs efficiently remove ET-1 from the 
circulation via binding to its presumed clearance receptor ETBR(86; 87; 168). Other 
investigators have previously found reduced pulmonary density of ETBR and reduced 
fractional extraction of ET-1 in HF models, indicating failure of the lungs to remove ET-1 in 
HF(80; 169). The relative contributions of altered clearance or production of ET-1 to raise 
plasma ET-1 levels in HF remained yet to be investigated(87; 168; 170). We found the 
pulmonary fractional extraction of plasma ET-1 to be about halved in HF pigs. However, 
fractional ET-1 extraction does not take into consideration the circulating plasma volume per 
time unit (cardiac output). Clearance of ET-1, i.e. the absolute amounts of ET-1 being 
removed from the circulation per minute, was not altered, contrasting with previous 
reports(80). However, that study was performed in rats with HF post-MI, and with ET-1 
clearance determined in lungs ex vivo. Another important finding of the present study was that 
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pulmonary synthesis of ET-1 was enhanced and correlated significantly with markers of LV 
filling pressures (LVEDP and PCWP). Augmented ECE-1 activity in congested pulmonary 
tissue was identified as important molecular mechanism for increased pulmonary synthesis of 
ET-1 in HF. These novel findings clearly illustrate the relevance of pulmonary congestion and 
pulmonary endothelial dysfunction for ET-1 activation. 
 Caution has, however, to be exerted when extrapolating these data in order to reach a broader 
understanding of HF. The pacing overdrive model employed her induces homogenous 
eccentric LV remodeling, generating a stable, predictable and relatively homogenous 
experimental HF cohort, but cardiac ultrastructural changes may differ from those observed in 
HF post MI(171; 172). Yet, LV dilatation and dysfunction, peripheral vasoconstriction, and 
neurohormonal activation including that of the ET-1 system, share important similarities with 
human dilated HF(173-177).  
 
Possible implications for future management of HF 
ET-1 is a multifunctional peptide governing numerous and complex biological functions in 
the cardiovascular system. The data presented in this study underbuild the notion that ET-1 is 
an important player in the pathogenesis of HF. Targeting of GPCRs in HF is of proven benefit 
in the case of 1-AR, but has not produced similar beneficial outcomes when targeting ETR. 
In the future, alternative approaches to counteract ET-1 mediated actions should be pursued, 
such as targeting biosynthesis at its molecular and cellular sources. ECE-1 inhibitors have 
been shown to produce similar acute vasodilator effects as ETAR antagonists in HF patients 
already on ACE inhibitor treatment(91; 178). ECE-1 antagonists have been shown to 
normalize ET-1 levels; and several approaches targeting ECE-1 individually or as dual ECE-
1/NEP inhibition or triple ECE-1/NEP/ACE inhibition have produced functional benefits in 
experimental and human HF(179-184). Besides ECE-1, also NEP and chymase may convert 
 25
bigET-1 to fully mature ET-1; thus, agents inhibiting multiple peptidases may be required. 
However, as both ECE-1, NEP and ACE also participate in the hydrolysis of bradykinin, 
putative adverse effects by accumulation of bradykinin need to be considered when triple 
inhibitors are employed(185; 186). Data from larger RCTs testing the concept of inhibiting 
ET-1 biosynthesis are lacking(48; 184). 
 
Effects of macrophage depletion on ET-levels and LV remodeling in HF after MI  
In the second paper, following up on findings in paper 1, we aimed to further explore the 
importance of specific components of the innate immunity, i.e. PM, for ET-1 synthesis and 
HF progression. Based on successful protocols of PM targeting in a model of PAH and right-
sided HF, we administered GdCl3 in the classical ischemic HF rat model, commencing two 
weeks after induction of a large MI with evidence of HF(187). Immunohistochemical and 
molecular analysis indicated successful PM depletion. The study provided first evidence that 
targeting PM significantly reduced systemic and pulmonary ET-1 levels as well as halted 
cardiac remodeling. There are several important considerations relating to the intervention as 
well as the assumed mode of action of GdCl3. Neither GdCl3 itself nor the chosen route of 
administration may provide entirely selective and specific targeting of PM. More likely, 
GdCl3  may affect several types of actively phagocytosing cells in liver and lungs as well as 
other organs, i.e. liver, spleen and kidneys(188; 189). For instance, there is evidence that 
GdCl3  interferes with hepatic Kupffer cell function, and reduces pro-inflammatory cytokines 
in sepsis or liver ischemia-reperfusion models(190-195). Moreover, even after first passage 
through the lungs, relevant amounts of GdCl3 could have reached the myocardium to exert 
positive inotropic effects as demonstrated at least in vitro in a dilated cardiomyopathy HF 
model(196). Nevertheless, several lines of evidence support the effectiveness of the 
intervention: First, massive apoptosis of CD68-positive cells in lung tissue were found in 
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GdCl3 -treated HF rats. Next, cardiac tissues showed only few CD68 positive cells, little 
apoptosis, and no differences between HF groups (data not shown). Last, trans-pulmonary 
gradients of plasma ET-1 as well as pulmonary tissue ET-1 and IL-12A and IL-12B levels 
were substantially reduced by the intervention. However, due to the small animal size, it was 
not feasible to perform experiments deciphering the relative contribution of pulmonary 
clearance and synthesis of ET-1, as in paper 1.  
The putative importance of PM in ET-1 biosynthesis and functional progression in HF needs 
to be corroborated in future studies. Both application of tissue- and cell-specific drugs and 
genetic targeting of PM or PM-related cytokines may be valuable and technically feasible 
strategies.  
 
Inhibition of myocardial GRK3 in vivo enhances contractility and 1-AR signaling  
Specific aspects of GPCR signaling, i.e. the role of myocardial GRK3 in regulation of cardiac 
function in vivo, were addressed in papers III and IV. GRK2 (formerly ARK-1), the isozyme 
of GRK3 has been shown to be regulated in experimental and human HF, and inhibition of 
GRK2 provided rescue of cardiac function in several HF models(150; 152; 153; 155-159). 
GRK3, previously thought to be subservient to its isozyme GRK2, is increasingly appreciated 
as a novel important regulatory kinase. Unlike GRK2, GRK3 does not seem to be regulated in 
cardiac tissue in HF(197). However, its selective expression in cardiomyocytes may imply an 
important functional role(197). Previous studies, performed in transgenic mice with cardiac-
restricted overexpression of GRK3, revealed specificity of GRK3 to desensitize 1B-AR and 
thrombin receptor, while 1-AR and Ang II signaling were not altered(160; 161). To date, 
studies of cardiac-specific targeting of GRK3 in vivo are lacking. A recent report from our 
laboratory provided in vitro evidence of striking differences in receptor specificities of GRK2 
and GRK3 in adult rat cardiomyocytes(162). It could be clearly shown that GRK3, but not 
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GRK2, regulated 1-AR and ET-R, while GRK2 or its peptide inhibitor reduced and 
enhanced 1-AR signaling, respectively. To study these findings in vivo, we generated 
transgenic mice expressing a peptide inhibitor of GRK3 (GRK3ct) in the myocardium, which 
exhibit phenotype with enhanced cardiac function and elevated blood pressure. Evidence of 
subtle LV diastolic dysfunction was found in the GRK3ct mice although the relevance of 
these ex vivo findings at very high filling pressures is uncertain. By ex vivo and in vivo 
experiments, GRK3 was identified to modulate 1-AR and ET-R, but not 1-AR. The 
dominant 1-AR subtypes in mice appear to be 1A-AR and 1B-AR. While cardiac-restricted 
overexpression of the 1A-AR in transgenic mice increased contractility in the absence of 
hypertrophy, overexpression of the 1B-AR induced early diastolic dysfunction and 
progression towards overt dilated HF later on(198-200). We did not succeed in identifying 
which 1-AR subtype was modulated most by GRK3ct expression, but the phenotypic 
findings point to predominant augmentation of 1A-AR signaling.  
Several aspects of the study, in particular relating to the transgenic model need to be 
discussed as important limitations. Cardiac myocyte-restricted expression of an inhibitory 
peptide, i.e. GRK3ct; may not only inhibit GRK3; an argument already raised in the case of 
GRK2ct. Apart from GRK3, other PH domain-containing proteins might be inhibited. 
GRK3ct may in fact inhibit GRK2, and although data obtained in rat cardiomyocytes ex vivo 
demonstrated selectivity of GRK3ct peptides for GRK3, we cannot exclude such effects to 
occur in mice in vivo(162). However, the lack of enhanced 1-AR signaling in the present 
study argues against relevant inhibition of GRK2. Moreover, even though not observed in our 
experiments, downstream regulation by sequestration of G could have occurred, leading to 
altered G-mediated signaling. However, the distinct specificities of GRK3ct compared to 
GRK2ct at the functionally most important cardiac GPCR and the similar specificities of the 
corresponding kinases GRK3 and 2 argue against sequestration of G(162).  
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To substantiate the findings presented here, alternative routes of manipulating GRK3-
mediated signaling should be pursued. For instance, targeted deletion of cardiac GRK3 (i.e. 
cardiac specific knock-out of GRK3, GRK3-KO) could be performed. Previously, enhanced 
chronotropic component of the baroreceptor reflex has been described in a general GRK3-KO 
model(167). However, blood pressure was not determined in that paper, making judgments on 
possibly altered 1-AR mediated enhancement of heart rate after nitroprusside administration 
difficult. Also, the lack of cardiac-selectivity in that genetic model obscures interpretation, 
and to date no further studies have been conducted attempting to clarify these findings. To 
gain more knowledge on putative dose-response effects of GRK3 manipulation on distinct 
GPCR signaling, supplemental functional studies in transgenic mice with different cardiac 
expression levels of GRK3 or an inhibitor would be needed. 
 
GRK3 inhibition rescues pressure-overload induced cardiac dysfunction 
In paper four, we extended our study on the regulatory role of GRK3 on cardiac function into 
a pathophysiological setting. In a pressure-overload model, inhibition of GRK3 prevented 
development of HF, and preserved cardiac function, while induction of pathological LVH 
itself was not altered. To exclude peripheral circulatory effects, comprehensive analysis of LV 
pressure-volume relations both in vivo and ex vivo were performed. An interesting observation 
is the lack of GRK3ct to augment increases of cardiac mass after pressure-overload, compared 
to our findings after chronic 1-AR stimulation. This behaviour resembles indeed that of 
GRK2ct in comparable settings(201; 202). One readily available explanation might be a 
concomitant GRK3ct-mediated enhancement of pro-hypertrophic pathways such as via 1B-
AR, being counteracted by beneficial 1A-AR-mediated enhancement of cardiac function in 
resisting high afterload, resulting in a neutral net effect on cardiac mass. In addition, pressure-
overload induced hypertrophy also occurs through activation of neurohormones such as Ang 
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II and ET-1; mediators which did not evoke enhanced ERK1/2 activation in cardiomyocytes 
of GRK3ct mice compared NLC mice (fig. 6, paper 3). Phosducin, a G-binding protein that 
does not resensitize -ARs, enhances contractility of failing cardiomyocytes in a similar 
fashion as GRK2ct(203), and in the absence of increased -AR-stimulated cAMP formation. 
Conceptually, the effects of GRK2ct could at least partially be due to inhibition of G rather 
than -AR resensitization. In view of the current findings that GRK3ct mediates similar 
cardioprotection as GRK3ct,  at least some of the beneficial effects could involve signal 
transduction via common downstream pathways, including G-mediated effects. Recent data 
showed G-dependent phosphoinositide 3-kinase (PI3K) activation in afterload-induced 
cardiac hypertrophy(204). The same group also demonstrated PI3K to form a cytosolic 
complex with GRK2, leading to GRK2-mediated translocation of PI3K to the membrane with 
subsequent attenuation of -AR sequestration (205). These data were supported by evidence 
for preserved -AR function and restored cardiac function through inhibition of receptor-
localized PI3K in several HF models (206; 207).  
In order to decisively establish a protective role for GRK3 inhibition in HF, several strategies 
would be applicable. MI-induced HF or volume overload models would need to be applied in 
order to address the impact of particular stressor stimuli on GRK3 signaling. Ongoing projects 
are going to evaluate cardiac function in hybrids of GRK3ct mice or mice with cardiac-
specific GRK3-KO cross-bred with genetic HF mice. Findings obtained in experimental 
models may eventually be tested by adequate pharmaceutical interventions, i.e. application of 
small-molecule approaches(208). If successful, this may provide the basis for testing GRK3 
modulation in human HF.  
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8. Conclusions 
1. In a large animal model, the lungs were identified as the most important contributors 
to elevated plasma ET-1 levels in severe HF. Pulmonary synthesis and release of ET-
1were increased, while pulmonary clearance of ET-1 remained unaltered. Increased 
ECE-1 isozyme activity in congested pulmonary tissue was identified as an important 
mechanism, with pulmonary macrophages (PM) appearing as novel cellular sites of 
increased synthesis of ET-1. 
2. In post-MI HF in rats, treatment with the macrophage toxicant GdCl3  for 21 days 
induced massive apoptosis of PM, lowered inflammatory cytokines and plasma levels 
of ET-1, and eliminated the trans-pulmonary gradient of ET-1. Importantly, 
macrophage depletion halted progressive cardiac dysfunction and HF after MI.  
3. Cardiac-specific inhibition of GRK3 in transgenic mice induces modest cardiac 
hypercontractility and hypertension, with structurally normal hearts. GRK3 inhibition 
increased responsiveness to 1-AR stimulation, while response to 1-AR stimulation 
was unaltered.  
4. Inhibition of GRK3 did not affect cardiac hypertrophy upon chronic pressure-
overload. However, cardiac function was preserved in Tg-GRK3ct compared to NLC 
mice, indicating a protective role of GRK3 inhibition in this HF model. 
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